SCHEMBL20370331

SCHEMBL20370331

CCCCC1=CC(=O)CC(C)(C)C1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
LMNA P02545 1/20 0.49
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HPGD P15428 1/20 0.40
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
APEX1 P27695 1/20 0.37
PAX8 Q06710 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7057576 0.89 LMNA (0.51) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL12459980 0.81 MAPT (0.41) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL19621118 0.80 LMNA (0.50) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL1071303 0.75 ALDH1A1 (0.46) MAPTLMNAALDH1A1MEN1KMT2A
Undecane SCHEMBL8674618 0.74 MAPT (0.59) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL20370333 0.74 MEN1 (0.55) LMNAALDH1A1MEN1KMT2AHPGD
SCHEMBL24531686 0.73 ALDH1A1 (0.44) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL1022486 0.72 ALOX5 (0.36)
SCHEMBL10792171 0.71 TSHR (0.49) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL9276218 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074861-A1 Anticonvulsant Compounds OWEN BARRY PHARMACEUTICALS INC (CA) 2025-03-06 US disclosed
US-11952338-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS INC. (CA) 2024-04-09 US disclosed
US-11345652-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS (CA) 2022-05-31 US disclosed
US-11345652-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS (CA) 2022-05-31 US disclosed
US-20210017116-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2021-01-21 US disclosed
US-20200148623-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2020-05-14 US disclosed
US-10556853-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS INC. (CA) 2020-02-11 US disclosed
WO-2018129609-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2018-07-19 WO disclosed
US-20180194715-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2018-07-12 US disclosed
US-20180194715-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2018-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952338-B2 Anticonvulsant compounds GABRE, CACNA1B, GRIK5 MAPT 1725/4885LMNA 4238/4885ALDH1A1 1140/4885
US-20180194715-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 MAPT 1725/4885LMNA 4238/4885ALDH1A1 1140/4885
US-20210017116-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 MAPT 1725/4885LMNA 4238/4885ALDH1A1 1140/4885
US-20200148623-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 MAPT 1725/4885LMNA 4238/4885ALDH1A1 1140/4885
US-11345652-B2 Anticonvulsant compounds GABRE, CACNA1B, GRIK5 MAPT 1725/4885LMNA 4238/4885ALDH1A1 1140/4885
US-20250074861-A1 Anticonvulsant Compounds GABRE, CACNA1B, GRIK5 MAPT 1725/4885LMNA 4238/4885ALDH1A1 1140/4885
US-10556853-B2 Anticonvulsant compounds GABRE, CACNA1B, GRIK5 MAPT 1725/4885LMNA 4238/4885ALDH1A1 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.